Targeted treatment matching and better trial access for gynecologic cancers
Gynecologic cancer care: Improving clinical trial enrollment through molecular matching with targeted therapies and improving access to care and research
['FUNDING_OTHER'] · OHIO STATE UNIVERSITY · NIH-11191381
This project helps people with gynecologic cancers get matched to targeted medicines based on their tumor's molecular profile and makes clinical trials easier to join.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11191381 on ClinicalTrials.gov |
What this research studies
You would benefit from a program that checks tumor DNA and other molecular features to find targeted therapies or trials that fit your cancer. The team at Ohio State will build a system to match patients to molecularly driven clinical trials and improve how patients are referred and enrolled. They will work with their comprehensive cancer center resources and with partners nationally to reach more people, including underrepresented groups. The goal is faster, fairer access to trials and therapies guided by each patient’s tumor biology.
Who could benefit from this research
Good fit: Ideal candidates are people with gynecologic cancers—especially endometrial or other uterine cancers—with molecular testing results or who are willing to have their tumor tested for actionable mutations or mismatch repair status.
Not a fit: Patients without targetable molecular changes, those not eligible for the linked clinical trials, or people with non-gynecologic cancers are unlikely to benefit directly from this effort.
Why it matters
Potential benefit: If successful, more patients could receive treatments matched to their tumor type, avoid ineffective therapies, and have better chances of improved outcomes.
How similar studies have performed: Molecular matching and targeted therapy trials have shown promise in gynecologic and other cancers (for example, immunotherapy benefit in mismatch repair–deficient tumors), but enrollment barriers remain and this project focuses on improving access.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BACKES, FLOOR J. — OHIO STATE UNIVERSITY
- Study coordinator: BACKES, FLOOR J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancers, Comprehensive Cancer Center